## Abstract The prognosis of pancreatic cancer is extremely poor with a 5‐year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T‐lymphocyte (CTL) precursors reacting to peptide
The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes
✍ Scribed by M. Lindauer; T. Stanislawski; Annett Häußler; Edith Antunes; Anne Cellary; Christoph Huber; M. Theobald
- Publisher
- Springer
- Year
- 1997
- Tongue
- English
- Weight
- 554 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0946-2716
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Nitrogen containing‐bisphosphonates (N‐BPs), widely used to treat bone diseases, have direct antitumor effects __via__ the inactivation of Ras proteins. In addition to the direct antitumor activities, N‐BPs expand gdγδT cells, which exhibit major histocompatibility complex‐unrestricted
We have derived HLA-A2.1-restricted, gastric cancerspecific cytotoxic T lymphocyte (CTL) lines by repetitive in vitro stimulation of tumor-associated lymphocytes (TAL) with autologous tumor cells. The HER2/neu specificity of these gastric cancer-specific CTLs was demonstrated using HER2/neu-transfec
## Abstract Despite several ongoing clinical trials of immunotherapies against glioma, few glioma‐specific antigens recognized by cytotoxic T lymphocytes (CTLs) have been identified. We recently demonstrated that intratumoral inoculation with herpes simplex virus (HSV) as a cancer vaccine activates